Revolutionising Bacterial Diagnostics

NANOPLEX technology enables rapid identification of infection within 15 minutes.

  • Learn More

Revolutionising Bacterial Diagnostics

NANOPLEX technology enables rapid identification of infection within 15 minutes.

  • Learn More

“Around 700,000 people around the world die annually due to drug-resistant infections. If no action is taken, it has been estimated that drug-resistant infections will kill 10 million people a year by 2050”

Dame Sally Davies, UK Chief Medical Officer (AMR review)

1
Hour delay in current testing
0
Increase in daily antibiotic use
0
Hospitalised with resistant infections (UK)

Our Mission

“Fighting Antimicrobial Resistance with Rapid POC diagnostics”

FluoretiQ have developed NANOPLEX™- a rapid diagnostic platform that identifies and enumerates bacterial pathogens in less than 15 minutes; ensuring that patients receive the most effective antibiotic treatment from the start.  

NANOPLEX™ uses a library of glycan-based probes that have been engineered to exploit the adhesion phase of infection. Our chemistry is tuned to be able to assign identity within a sample and determine whether a clinically significant concentration is present.

Our probe library can currently identify 95% of commonly identified uropathogens including Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus saprophyticus.

Fluoretiq

A message from our CEO, Neciah Dorh

“Even with new drugs under development, the only way to safeguard the future is to develop the right diagnostic tools to allow us to quickly identify bacteria at the point of consultation”

NANOPLEX can offer clinical information to the physician at the point of care, reducing the need for empirical antibiotic use”.

Saving Time, Saving Money, Saving Lives.

LATEST NEWS

The RUBIvet project is live!

What is the RUBIvet project? We have developed NANOPLEX™ technology for rapid identification of bacterial infections in 15 minutes. The RUBIvet project enables us to further diversify our R&D pipeline through…

Winner of the AMR Start-up Campus

FluoretiQ were honoured to present NANOPLEX™ at BIOCOM ‘s 4th Annual AMR Conference to an international audience of experts in Antimicrobials and AMR diagnostics. In an interview with CEO, Neciah…

Winners at the Launch Great West Awards

FluoretiQ are the winners of The People’s Choice Award at the Launch: Great West event The People’s Choice Award invites attendees to nominate their choice for the best scientific start-up…

TEDxBristol: 2019

“It’s expected that by 2050, superbug infections will kill more people than cancer” TEDxBristol 2019 #ReflectRethinkReboot was all about taking moments to honestly on where we are at with some…

Join the NANOPLEX Revolution!

Menu